Foghorn Therapeutics vs Zymeworks
FHTX and ZYME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FHTX and ZYME compare
Zymeworks is the larger company, worth 17 times as much as Foghorn Therapeutics ($2.1B against $124M).
On earnings, Foghorn Therapeutics is cheaper: it trades at 29.9× trailing earnings, against 55.9× for Zymeworks.
Foghorn Therapeutics grew revenue faster over the last twelve months (357% versus 97.8% for Zymeworks).
Zymeworks keeps more of each dollar of sales as profit, with a net margin of 16.3% compared with 8.4% at Foghorn Therapeutics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FHTX | ZYME |
|---|---|---|
| Size and price | ||
| Market cap | $124M | $2.1B |
| Share price | $2.09 | $29.07 |
| Change, 1 year | −52.7% | 61.1% |
| Change, 5 years | −84.7% | 46.7% |
| Beta (5Y) | 1.87 | 0.84 |
| Employees | 106 | 264 |
| StockData Score | ||
| Total score | 10 | 10 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 4 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 29.9× (better) | 55.9× |
| P/S | 1.1× (better) | 7.8× |
| P/B | – | 8.0× |
| EV/EBITDA | 11.5× (better) | 44.4× |
| FCF yield | −67.4% | −5.5% (better) |
| Fair value | $2.08 | $12.06 |
| Margin of safety | −0.44% (better) | −141% |
| Growth | ||
| Revenue growth (TTM) | 357% (better) | 97.8% |
| Revenue growth, 5Y average | 135% (better) | 22.2% |
| Profitability | ||
| Operating margin | 2.1% | 16.6% (better) |
| Net margin | 8.4% | 16.3% (better) |
| FCF margin | −74.6% | −42.4% (better) |
| Return on equity | – | 15.0% |
| Return on invested capital | – | 21.4% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 4.24 (better) | 3.30 |
| Altman Z-score | −2.66 | 0.87 (better) |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 8.0% |
| Shareholder yield | 0.00% | 8.0% (better) |
| Ownership | ||
| Held by institutions | 75.6% | 98.1% |
| Held by insiders | 36.3% | 58.9% |
| Insider net buying, 12 months | – | −$5.0M |
| Short interest, % of float | 6.0% | 20.3% |
Go deeper
- FHTX stock overview
- FHTX income statement
- FHTX valuation and score
- ZYME stock overview
- ZYME income statement
- ZYME valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.